View Older Stories View More Recent Stories

Aug 13, 2024 08:00AM Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Aug 12, 2024 04:01PM Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
Aug 5, 2024 08:00AM Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024
Jul 19, 2024 08:00AM Dare Bioscience (DARE) Regains Nasdaq Compliance
Jul 19, 2024 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Jul 1, 2024 06:54AM Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Jun 27, 2024 08:04AM Dare Bioscience (DARE) Announces 1:12 Reverse Share Split
Jun 27, 2024 08:00AM Daré Bioscience Announces Reverse Stock Split
Jun 24, 2024 08:00AM Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder
May 14, 2024 08:00AM Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
May 7, 2024 08:00AM Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
May 2, 2024 08:00AM Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
Apr 30, 2024 07:30AM Dare Bioscience (DARE) Secures $22M in Non-Dilutive Strategic Royalty Financing
Apr 30, 2024 07:30AM Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Apr 23, 2024 08:03AM Dare Bioscience (DARE) Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Apr 23, 2024 08:00AM Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Apr 11, 2024 08:00AM Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intrava
Mar 28, 2024 08:00AM Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Mar 21, 2024 08:00AM Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Feb 22, 2024 08:00AM Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Jan 31, 2024 08:05AM Dare Bioscience (DARE) Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream
Jan 31, 2024 08:00AM Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Jan 26, 2024 04:34PM Dare Bioscience (DARE) Announces Board Changes
Jan 26, 2024 04:30PM Daré Bioscience Announces Executive Team and Board of Directors Changes
Jan 17, 2024 08:05AM Dare Bioscience (DARE) Announces Grant to Support Biotherapeutic Product Development
Jan 17, 2024 08:00AM Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Jan 4, 2024 08:07AM Dare Bioscience (DARE) DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Jan 4, 2024 08:00AM Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Dec 26, 2023 08:00AM Dare Bioscience (DARE) Secures $12M in Royalty-backed Investment Structure
Dec 26, 2023 08:00AM Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Dec 20, 2023 08:02AM Dare Bioscience (DARE) Reports Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Study
Dec 20, 2023 08:00AM Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Dec 13, 2023 08:01AM Dare Bioscience (DARE) Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DA
Dec 13, 2023 08:00AM Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB
Dec 7, 2023 08:08AM Dare Bioscience (DARE) Announces FDA Clearance of IND Application for DARE-VVA1
Dec 7, 2023 08:00AM Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vul
Dec 4, 2023 08:00AM Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Nov 20, 2023 08:00AM Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
Nov 13, 2023 08:00AM Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
Nov 9, 2023 08:00AM Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Nov 6, 2023 08:00AM Daré Bioscience to Participate in Three November Conferences
Nov 2, 2023 08:00AM Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023
Nov 1, 2023 08:01AM Dare Bioscience (DARE) Reports Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream
Nov 1, 2023 08:00AM Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
Oct 16, 2023 08:07AM Dare Bioscience (DARE) Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO Vaginal Gel, 2%
Oct 16, 2023 08:00AM Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in F
Sep 21, 2023 08:04AM Dare Bioscience (DARE) Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Sep 21, 2023 08:00AM Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Sep 20, 2023 08:00AM Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting
Sep 6, 2023 08:00AM Daré Bioscience to Participate in Upcoming Investor Conferences
View More Recent Stories View Older Stories